KNApSAcK Metabolite C00001382
Metabolite
KNApSAcK Entry
| id | C00001382 |
|---|---|
| Name | Se-methyl-L-selenocysteine |
| CAS RN | 2574-71-2 |
| Standard InChI | InChI=1S/C4H9NO2Se/c1-8-2-3(5)4(6)7/h3H,2,5H2,1H3,(H,6,7)/t3-/m0/s1 |
| Standard InChI (Main Layer) | InChI=1S/C4H9NO2Se/c1-8-2-3(5)4(6)7/h3H,2,5H2,1H3,(H,6,7) |
Cluster
| Phytochemical cluster | |
|---|---|
| KCF-S cluster | No. 2513 |
Link
ChEMBL
| By standard InChI | CHEMBL62382 |
|---|---|
| By standard InChI Main Layer | CHEMBL62382 CHEMBL1472699 |
KEGG
| By LinkDB | C05689 |
|---|
CTD
| By CAS RN | C002979 |
|---|
Species
Summary
Family
| family name | count |
|---|---|
| Fabaceae | 1 |
| Asteraceae | 1 |
List (2)
* NCBI
| KNApSAcK organism | *ID | *family | *plant class | *kingdom |
|---|---|---|---|---|
| Astragalus bisulcatus | 20406 | Fabaceae | rosids | Viridiplantae |
| Oonopsis condensata | 71082 | Asteraceae | asterids | Viridiplantae |
Human Protein / Gene in interaction
16 ChEMBL Protein in interactions
| accession | description | class description | compound | assay ID (# of activities) |
# of diseases
(OMIM / KEGG) |
|---|---|---|---|---|---|
| P10635 | Cytochrome P450 2D6 | Cytochrome P450 2D6 | CHEMBL1472699 |
CHEMBL1741321
(1)
|
1 / 0 |
| Q99700 | Ataxin-2 | Unclassified protein | CHEMBL62382 |
CHEMBL1794367
(1)
|
1 / 1 |
| P49798 | Regulator of G-protein signaling 4 | Unclassified protein | CHEMBL62382 |
CHEMBL1794499
(1)
|
2 / 0 |
| Q16773 | Kynurenine--oxoglutarate transaminase 1 | Enzyme | CHEMBL62382 CHEMBL1472699 |
CHEMBL857291
(1)
CHEMBL656041
(2)
CHEMBL656042 (1) CHEMBL858198 (1) |
0 / 0 |
| P16473 | Thyrotropin receptor | Glycohormone receptor | CHEMBL1472699 |
CHEMBL1614361
(1)
|
3 / 2 |
| P11712 | Cytochrome P450 2C9 | Cytochrome P450 2C9 | CHEMBL1472699 |
CHEMBL1741325
(1)
|
0 / 1 |
| Q16665 | Hypoxia-inducible factor 1-alpha | Transcription Factor | CHEMBL1472699 |
CHEMBL1614456
(1)
CHEMBL1613803
(1)
|
0 / 0 |
| P28482 | Mitogen-activated protein kinase 1 | Erk | CHEMBL1472699 |
CHEMBL1613808
(1)
|
0 / 0 |
| P05177 | Cytochrome P450 1A2 | Cytochrome P450 1A2 | CHEMBL1472699 |
CHEMBL1741322
(1)
|
0 / 0 |
| Q96QE3 | ATPase family AAA domain-containing protein 5 | Unclassified protein | CHEMBL62382 |
CHEMBL1738675
(1)
|
0 / 0 |
| P19838 | Nuclear factor NF-kappa-B p105 subunit | Transcription Factor | CHEMBL1472699 |
CHEMBL1614274
(1)
CHEMBL1613823
(1)
|
0 / 0 |
| P16050 | Arachidonate 15-lipoxygenase | Enzyme | CHEMBL1472699 |
CHEMBL1614240
(1)
|
0 / 0 |
| P33261 | Cytochrome P450 2C19 | Cytochrome P450 2C19 | CHEMBL1472699 |
CHEMBL1613777
(1)
CHEMBL1741323
(1)
|
1 / 1 |
| P08684 | Cytochrome P450 3A4 | Cytochrome P450 3A4 | CHEMBL1472699 |
CHEMBL1614108
(1)
CHEMBL1613886
(1)
CHEMBL1741324 (1) |
0 / 1 |
| Q16236 | Nuclear factor erythroid 2-related factor 2 | Unclassified protein | CHEMBL62382 |
CHEMBL1737980
(1)
|
0 / 0 |
| Q96KQ7 | Histone-lysine N-methyltransferase EHMT2 | Enzyme | CHEMBL62382 |
CHEMBL1738442
(1)
|
0 / 0 |
CTD interaction (46)
| compound | gene | gene name | gene description | interaction | interaction type | form |
reference
pmid |
|---|---|---|---|---|---|---|---|
| C002979 | 4363 |
ABCC1
ABC29 ABCC GS-X MRP MRP1 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 | [selenomethylselenocysteine co-treated with irinotecan] results in decreased expression of ABCC1 |
affects cotreatment
/ decreases expression |
15897249
|
|
| C002979 | 54971 |
BANP
BEND1 SMAR1 SMARBP1 |
BTG3 associated nuclear protein | selenomethylselenocysteine results in increased expression of BANP mRNA |
increases expression
|
mRNA |
18514395
|
| C002979 | 596 |
BCL2
Bcl-2 PPP1R50 |
B-cell CLL/lymphoma 2 | selenomethylselenocysteine results in decreased expression of BCL2 mRNA |
decreases expression
|
mRNA |
19360359
|
| C002979 | 596 |
BCL2
Bcl-2 PPP1R50 |
B-cell CLL/lymphoma 2 | [selenomethylselenocysteine results in decreased expression of BCL2 mRNA] which results in increased activity of TNFSF10 protein |
decreases expression
/ increases activity |
mRNA |
19360359
|
| C002979 | 595 |
CCND1
BCL1 D11S287E PRAD1 U21B31 |
cyclin D1 | [selenomethylselenocysteine co-treated with Tamoxifen] results in decreased expression of CCND1 protein |
affects cotreatment
/ decreases expression |
protein |
18855134
|
| C002979 | 595 |
CCND1
BCL1 D11S287E PRAD1 U21B31 |
cyclin D1 | selenomethylselenocysteine results in decreased expression of CCND1 protein |
decreases expression
|
protein |
18855134
|
| C002979 | 1066 |
CES1
ACAT CE-1 CEH CES2 HMSE HMSE1 PCE-1 REH SES1 TGH hCE-1 |
carboxylesterase 1 (EC:3.1.1.1 3.1.1.56) | selenomethylselenocysteine results in increased expression of CES1 |
increases expression
|
15897249
|
|
| C002979 | 5119 |
CHMP1A
CHMP1 PCH8 PCOLN3 PRSM1 VPS46-1 VPS46A |
charged multivesicular body protein 1A | selenomethylselenocysteine results in increased expression of CHMP1A mRNA |
increases expression
|
mRNA |
18514395
|
| C002979 | 1277 |
COL1A1
OI4 |
collagen, type I, alpha 1 | selenomethylselenocysteine results in decreased expression of COL1A1 mRNA |
decreases expression
|
mRNA |
18514395
|
| C002979 | 1277 |
COL1A1
OI4 |
collagen, type I, alpha 1 | selenomethylselenocysteine results in decreased expression of COL1A1 protein |
decreases expression
|
protein |
18514395
|
| C002979 | 1278 |
COL1A2
OI4 |
collagen, type I, alpha 2 | selenomethylselenocysteine results in decreased expression of COL1A2 mRNA |
decreases expression
|
mRNA |
18514395
|
| C002979 | 1278 |
COL1A2
OI4 |
collagen, type I, alpha 2 | selenomethylselenocysteine results in decreased expression of COL1A2 protein |
decreases expression
|
protein |
18514395
|
| C002979 | 1287 |
COL4A5
ASLN ATS CA54 |
collagen, type IV, alpha 5 | selenomethylselenocysteine results in increased expression of COL4A5 mRNA |
increases expression
|
mRNA |
18514395
|
| C002979 | 1291 |
COL6A1
OPLL |
collagen, type VI, alpha 1 | selenomethylselenocysteine results in increased expression of COL6A1 mRNA |
increases expression
|
mRNA |
18514395
|
| C002979 | 1294 |
COL7A1
EBD1 EBDCT EBR1 |
collagen, type VII, alpha 1 | selenomethylselenocysteine results in decreased expression of COL7A1 mRNA |
decreases expression
|
mRNA |
18514395
|
| C002979 | 1577 |
CYP3A5
CP35 CYPIIIA5 P450PCN3 PCN3 |
cytochrome P450, family 3, subfamily A, polypeptide 5 (EC:1.14.14.1) | [selenomethylselenocysteine co-treated with irinotecan] results in increased expression of CYP3A5 |
affects cotreatment
/ increases expression |
15897249
|
|
| C002979 | 4733 |
DRG1
NEDD3 |
developmentally regulated GTP binding protein 1 | [selenomethylselenocysteine co-treated with irinotecan] results in decreased expression of DRG1 |
affects cotreatment
/ decreases expression |
15897249
|
|
| C002979 | 2099 |
ESR1
ER ESR ESRA ESTRR Era NR3A1 |
estrogen receptor 1 | [selenomethylselenocysteine co-treated with Tamoxifen] results in decreased expression of ESR1 protein |
affects cotreatment
/ decreases expression |
protein |
18855134
|
| C002979 | 2099 |
ESR1
ER ESR ESRA ESTRR Era NR3A1 |
estrogen receptor 1 | selenomethylselenocysteine results in decreased expression of ESR1 protein |
decreases expression
|
protein |
18855134
|
| C002979 | 356 |
FASLG
ALPS1B APT1LG1 APTL CD178 CD95-L CD95L FASL TNFSF6 |
Fas ligand (TNF superfamily, member 6) | [selenomethylselenocysteine co-treated with irinotecan] results in increased expression of FASLG |
affects cotreatment
/ increases expression |
15897249
|
|
| C002979 | 2876 |
GPX1
GPXD GSHPX1 |
glutathione peroxidase 1 (EC:1.11.1.9) | selenomethylselenocysteine results in increased activity of GPX1 protein |
increases activity
|
protein |
19033020
|
| C002979 | 2876 |
GPX1
GPXD GSHPX1 |
glutathione peroxidase 1 (EC:1.11.1.9) | selenomethylselenocysteine results in increased expression of GPX1 mRNA |
increases expression
|
mRNA |
18514395
|
| C002979 | 2876 |
GPX1
GPXD GSHPX1 |
glutathione peroxidase 1 (EC:1.11.1.9) | selenomethylselenocysteine results in increased expression of GPX1 protein |
increases expression
|
protein |
19033020
|
| C002979 | 2879 |
GPX4
GPx-4 GSHPx-4 MCSP PHGPx snGPx snPHGPx |
glutathione peroxidase 4 (EC:1.11.1.12) | selenomethylselenocysteine results in increased expression of GPX4 mRNA |
increases expression
|
mRNA |
18514395
|
| C002979 | 2897 |
GRIK1
EAA3 EEA3 GLR5 GLUR5 GluK1 |
glutamate receptor, ionotropic, kainate 1 | selenomethylselenocysteine results in increased expression of GRIK1 mRNA |
increases expression
|
mRNA |
18514395
|
| C002979 | 2899 |
GRIK3
EAA5 GLR7 GLUR7 GluK3 GluR7a |
glutamate receptor, ionotropic, kainate 3 | selenomethylselenocysteine results in increased expression of GRIK3 mRNA |
increases expression
|
mRNA |
18514395
|
| C002979 | 3480 |
IGF1R
CD221 IGFIR IGFR JTK13 |
insulin-like growth factor 1 receptor (EC:2.7.10.1) | selenomethylselenocysteine results in increased expression of IGF1R mRNA |
increases expression
|
mRNA |
18514395
|
| C002979 | 4288 |
MKI67
KIA MIB-1 |
marker of proliferation Ki-67 | [selenomethylselenocysteine co-treated with Tamoxifen] results in decreased expression of MKI67 protein |
affects cotreatment
/ decreases expression |
protein |
18855134
|
| C002979 | 4288 |
MKI67
KIA MIB-1 |
marker of proliferation Ki-67 | selenomethylselenocysteine results in decreased expression of MKI67 protein |
decreases expression
|
protein |
18855134
|
| C002979 | 51734 |
MSRB1
SELR SELX SEPX1 SepR |
methionine sulfoxide reductase B1 (EC:1.8.4.-) | selenomethylselenocysteine results in increased expression of MSRB1 mRNA |
increases expression
|
mRNA |
18514395
|
| C002979 | 5033 |
P4HA1
P4HA |
prolyl 4-hydroxylase, alpha polypeptide I (EC:1.14.11.2) | selenomethylselenocysteine results in increased expression of P4HA1 mRNA |
increases expression
|
mRNA |
18514395
|
| C002979 | 5241 |
PGR
NR3C3 PR |
progesterone receptor | [selenomethylselenocysteine co-treated with Tamoxifen] results in decreased expression of PGR protein |
affects cotreatment
/ decreases expression |
protein |
18855134
|
| C002979 | 5241 |
PGR
NR3C3 PR |
progesterone receptor | selenomethylselenocysteine results in decreased expression of PGR protein |
decreases expression
|
protein |
18855134
|
| C002979 | 5865 |
RAB3B
|
RAB3B, member RAS oncogene family | selenomethylselenocysteine results in increased expression of RAB3B mRNA |
increases expression
|
mRNA |
18514395
|
| C002979 | 5867 |
RAB4A
HRES-1/RAB4 RAB4 |
RAB4A, member RAS oncogene family | selenomethylselenocysteine results in increased expression of RAB4A mRNA |
increases expression
|
mRNA |
18514395
|
| C002979 | 949 |
SCARB1
CD36L1 CLA-1 CLA1 HDLQTL6 SR-BI SRB1 |
scavenger receptor class B, member 1 | selenomethylselenocysteine results in increased expression of SCARB1 mRNA |
increases expression
|
mRNA |
18514395
|
| C002979 | 9403 |
SEP15
|
15 kDa selenoprotein | selenomethylselenocysteine results in increased expression of SEP15 mRNA |
increases expression
|
mRNA |
18514395
|
| C002979 | 6414 |
SEPP1
SELP SeP |
selenoprotein P, plasma, 1 | selenomethylselenocysteine results in increased expression of SEPP1 mRNA |
increases expression
|
mRNA |
18514395
|
| C002979 | 6415 |
SEPW1
selW |
selenoprotein W, 1 | selenomethylselenocysteine results in increased expression of SEPW1 mRNA |
increases expression
|
mRNA |
18514395
|
| C002979 | 6519 |
SLC3A1
ATR1 CSNU1 D2H NBAT RBAT |
solute carrier family 3 (amino acid transporter heavy chain), member 1 | SLC3A1 protein results in increased uptake of selenomethylselenocysteine |
increases uptake
|
protein |
18845132
|
| C002979 | 8773 |
SNAP23
HsT17016 SNAP-23 SNAP23A SNAP23B |
synaptosomal-associated protein, 23kDa | selenomethylselenocysteine results in decreased expression of SNAP23 mRNA |
decreases expression
|
mRNA |
18514395
|
| C002979 | 6272 |
SORT1
Gp95 LDLCQ6 NT3 |
sortilin 1 | selenomethylselenocysteine results in increased expression of SORT1 mRNA |
increases expression
|
mRNA |
18514395
|
| C002979 | 393515 | selenomethylselenocysteine results in increased expression of STX3A mRNA |
increases expression
|
mRNA |
18514395
|
||
| C002979 | 8743 |
TNFSF10
APO2L Apo-2L CD253 TL2 TRAIL |
tumor necrosis factor (ligand) superfamily, member 10 | [selenomethylselenocysteine results in decreased expression of BCL2 mRNA] which results in increased activity of TNFSF10 protein |
decreases expression
/ increases activity |
protein |
19360359
|
| C002979 | 54952 |
TRNAU1AP
PRO1902 RP4-669K10.4 SECP43 TRSPAP1 |
tRNA selenocysteine 1 associated protein 1 | selenomethylselenocysteine results in increased expression of TRNAU1AP mRNA |
increases expression
|
mRNA |
18514395
|
| C002979 | 7507 |
XPA
XP1 XPAC |
xeroderma pigmentosum, complementation group A | selenomethylselenocysteine inhibits the reaction [Zinc binds to XPA protein] |
affects binding
/ decreases reaction |
protein |
15265038
|
Related Disease
Diseases related to proteins in ChEMBL interactions
OMIM (8)
| OMIM | preferred title | UniProt |
|---|---|---|
| #609535 | Drug metabolism, poor, cyp2c19-related |
P33261
|
| #608902 | Drug metabolism, poor, cyp2d6-related |
P10635
|
| #603373 | Hyperthyroidism, familial gestational |
P16473
|
| #609152 | Hyperthyroidism, nonautoimmune |
P16473
|
| #275200 | Hypothyroidism, congenital, nongoitrous, 1; chng1 |
P16473
|
| #604906 | Schizophrenia 9; sczd9 |
P49798
|
| #181500 | Schizophrenia; sczd |
P49798
|
| #183090 | Spinocerebellar ataxia 2; sca2 |
Q99700
|
KEGG DISEASE (6)
| KEGG | disease name | UniProt |
|---|---|---|
| H00036 | Osteosarcoma |
P08684
(marker)
|
| H01205 | Coumarin resistance |
P11712
(related)
|
| H00250 | Congenital nongoitrous hypothyroidism (CHNG) |
P16473
(related)
|
| H01269 | Congenital hyperthyroidism |
P16473
(related)
|
| H01171 | Poor drug metabolism (PM) |
P33261
(related)
|
| H00063 | Spinocerebellar ataxia (SCA) |
Q99700
(related)
|
Diseases related to CTD interactions
6 disease from interactions of metabolites
| MeSH disease | OMIM | compound | disease name | evidence type |
reference
pmid |
|---|---|---|---|---|---|
| D001943 | C002979 | Breast Neoplasms |
marker/mechanism
|
18855134
|
|
| D056486 | C002979 | Drug-Induced Liver Injury |
marker/mechanism
|
17728283
|
|
| D006943 | C002979 | Hyperglycemia |
therapeutic
|
19010315
|
|
| D007003 | C002979 | Hypoglycemia |
marker/mechanism
|
19010315
|
|
| D007673 | C002979 | Kidney Cortex Necrosis |
marker/mechanism
|
19010315
|
|
| D008325 | C002979 | Mammary Neoplasms, Experimental |
therapeutic
|
15318939
|